A Phase 3 interventional study of Tanruprubart in Guillain-Barre Syndrome, sponsored by Annexon, Inc.. Recruiting at 30 sites in 5 countries. Open to participants aged 8 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Annexon, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Guillain-Barre Syndrome with a site in United States — 2 open to participants now, 2 under way, 1 of them phase 3. Guillain-Barre Syndrome · United States.
Among the 16 studies in Guillain-Barre Syndrome with a site in United States, this one is the only one that started in 2025, is the only one in phase 3, and was the 16th registered.
98 studies on the registry are indexed under Guillain-Barre Syndrome; 30 are open to participants now.
Browse Guillain-Barre Syndrome studies →2 of the 16 studies in Guillain-Barre Syndrome with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Guillain-Barre Syndrome studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 8 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1
First in 1995; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 50 across 44 interventional studies indexed under Guillain-Barre Syndrome.
Median enrollment 30 across the 6 interventional studies, 1,179 across the 10 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Annexon, Inc. is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Annexon, Inc. has 3 studies filed under Guillain-Barre Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Guillain-Barre Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07020819Phase 3Annexon, Inc.An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Guillain-Barre Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined criteria may apply.
Participants will receive a single 30 mg/kg intravenous (IV) infusion of tanruprubart on Day 1.
Drug: Tanruprubart
Solution for IV infusion.
Also known as: ANX005
Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t)
Time frame: Up to Day 15
Observed Time to Maximum Observed Serum Concentration (Cmax) (Tmax) of Tanruprubart
Time frame: Up to Day 15
Change From Baseline in Free Component of Complement Complex (C1q) Protein Concentration in Serum
Time frame: Baseline up to Day 15
Change from Baseline in Medical Research Council (MRC) Sumscore at Week 1
Time frame: Baseline, Week 1
Plan to share: No
Started Sep 2025 (actual). Primary completion is estimated for May 2027, 20 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → May 2027, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tanruprubart
Annexon, Inc.